No definition available.
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
E4_HYPERURI
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
172 |
4. Check minimum number of eventsNone |
172 |
5. Include endpointsNone |
172 |
6. Filter based on genotype QC (FinnGen only) |
167 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E79
- Name in latin
- Hyperurichaemia sine symptomatibus arthritidis inflammatoriae sive morbi tophacei
Similar endpoints
↥List of similar endpoints to
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
based on the number of shared cases.
Similar with more cases:
- Disorders of purine and pyrimidine metabolism
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1098 | 486 | 606 |
| Only index persons | 956 | 413 | 543 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 67.61 | 70.73 | 65.06 |
| Only index persons | 65.92 | 68.15 | 64.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 167 | 58 | 109 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 65.84 | 64.11 | 66.77 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 172
- Matched controls
- 1720
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E79.0
ICD-10 Finland
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
+∞
248.8
172
*
M04AA01
ATC
allopurinol; systemic
16.7
81.0
111
169
M10.9
ICD-10 Finland
Gout, unspecified
12.2
44.4
52
59
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
16.0
44.3
42
34
M10.0
ICD-10 Finland
Idiopathic gout
14.9
32.4
31
25
M13.9
ICD-10 Finland
Arthritis, unspecified
6.8
18.9
33
58
205
Kela drug reimbursment
Chronic hypertension
4.1
18.7
82
311
212
Kela drug reimbursment
Gout
22.2
17.5
25
13
C03CA01
ATC
furosemide; systemic
3.9
17.3
93
401
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.5
16.7
26
40
H02AB06
ATC
prednisolone; systemic
4.0
16.5
118
610
A10BH05
ATC
linagliptin; oral
7.1
16.0
26
42
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.6
15.5
27
47
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.5
14.9
43
118
N17.9
ICD-10 Finland
Acute renal failure, unspecified
15.3
14.7
24
18
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.5
14.4
42
116
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.5
13.1
64
251
A10BA02
ATC
metformin; oral
3.3
13.0
73
312
103
Kela drug reimbursment
Diabetes, insulin-treated
3.3
12.6
70
297
A46
ICD-10 Finland
Erysipelas
3.8
12.5
47
155
C07AB07
ATC
bisoprolol; oral
3.3
12.5
117
671
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.7
12.4
25
50
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.9
11.9
23
44
E66.00
ICD-10 Finland
Metabolic syndrome
6.3
11.8
21
37
288
Kela drug reimbursment
Febuxostat
69.9
11.8
13
*
C10AA01
ATC
simvastatin; oral
3.0
11.6
96
506
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
3.8
11.6
43
140
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.4
11.3
24
50
C03DA01
ATC
spironolactone; oral
3.9
11.2
38
116
C10AA05
ATC
atorvastatin; oral
2.9
11.0
95
508
E66.01
ICD-10 Finland
Obesity due to excess calories
5.1
10.9
25
56
349
Kela drug reimbursment
Febuxostat
64.1
10.8
12
*
M04AA03
ATC
febuxostat; oral
64.1
10.8
12
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.3
10.7
31
84
A07EC01
ATC
sulfasalazine; oral, rectal
4.8
10.5
26
62
C08CA01
ATC
amlodipine; oral
2.8
10.4
91
487
I10
ICD-10 Finland
Essential (primary) hypertension
3.2
10.3
130
843
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.0
9.8
59
256
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
9.8
104
608
AN1
HP
Coronary angiography
3.9
9.7
32
95
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
9.6
51
206
P01BA02
ATC
hydroxychloroquine; oral
4.2
9.6
28
76
I50.9
ICD-10 Finland
Heart failure, unspecified
3.3
9.6
45
169
H02AB07
ATC
prednisone; oral
3.6
9.6
37
123
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.8
9.3
67
319
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.9
9.3
59
263
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
16.8
9.2
14
9
N18.8
ICD-10 Finland
Other chronic renal failure
13.6
9.1
15
12
J01DB01
ATC
cefalexin; oral
4.3
9.0
154
1144
T90
ICPC
Diabetes non-insulin dependent
2.9
8.9
57
254
E86
ICD-10 Finland
Volume depletion
52.7
8.8
10
*
E66.8
ICD-10 Finland
Other obesity
10.9
8.7
16
16
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
21.3
8.6
12
6
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
13.7
8.5
14
11
C09CA03
ATC
valsartan; oral
3.9
8.5
27
78
J01FF01
ATC
clindamycin; systemic
2.7
8.4
66
326
N19
ICD-10 Finland
Unspecified kidney failure
8.9
8.3
17
21
L28
ICPC
Limited function/disability (L)
2.9
8.3
47
196
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
35.2
8.2
10
*
L04AX03
ATC
methotrexate; systemic
3.6
7.9
28
87
A10AB05
ATC
insulin aspart; parenteral
4.1
7.9
23
62
A11CC03
ATC
alfacalcidol; systemic
16.0
7.8
12
8
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.9
7.7
24
68
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.2
7.7
35
128
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
3.3
7.6
31
106
M01AB01
ATC
indometacin; systemic, rectal
3.6
7.5
27
85
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
6.3
7.5
19
33
A10AC01
ATC
insulin (human); parenteral
4.1
7.5
22
60
A10BK01
ATC
dapagliflozin; oral
4.3
7.4
20
51
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.5
7.4
27
86
A10AE04
ATC
insulin glargine; parenteral
3.6
7.2
25
77
G47.3
ICD-10 Finland
Sleep apnoea
2.6
7.1
54
260
E0000UV, ,
ATC
2.4
7.0
78
446
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
11.6
6.9
12
11
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.9
6.9
38
155
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.7
6.8
45
202
E66.9
ICD-10 Finland
Obesity, unspecified
8.4
6.8
14
18
N17.8
ICD-10 Finland
Other acute renal failure
23.6
6.7
9
*
JN3AD
NOMESCO Finland
Abdominal CT examination
3.3
6.7
27
91
A10AE05
ATC
insulin detemir; parenteral
4.5
6.7
17
41
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
4.5
6.7
17
41
C02AC05
ATC
moxonidine; oral
5.8
6.7
18
34
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
6.7
71
397
B01AF02
ATC
apixaban; oral
2.9
6.6
35
139
C09AA02
ATC
enalapril; systemic
2.6
6.6
49
232
I50.0
ICD-10 Finland
Congestive heart failure
3.5
6.6
24
76
A10BH01
ATC
sitagliptin; oral
3.2
6.6
28
98
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
6.4
42
187
R06.0
ICD-10 Finland
Dyspnoea
2.4
6.3
61
325
R03AC02
ATC
salbutamol; inhalant
2.3
6.3
103
683
R50.9
ICD-10 Finland
Fever, unspecified
2.8
6.2
36
150
N02AA05
ATC
oxycodone; systemic
2.5
6.2
45
211
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.9
6.1
32
126
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
10.6
6.1
11
11
J01MA14
ATC
moxifloxacin; systemic
3.3
6.1
24
80
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
3.7
6.1
20
59
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
123
369
9.19
44.91
6.0
2.6
421.65
7599.72
umol/l
1.76
112
310
65
201
4.59
19.75
4.7
2.0
2.25
2.28
g/l
0.19
60
187
63
193
4.57
19.33
4.8
2.1
19.18
23.14
%
1.79
56
165
67
223
4.28
18.29
4.7
2.1
10.83
13.24
umol/l
2.21
62
205
125
656
4.31
17.44
16.3
6.4
1.19
1.21
mmol/l
1.24
104
556
119
610
4.09
17.03
14.9
5.8
1.19
1.21
mmol/l
0.99
111
548
43
117
4.57
15.03
9.8
3.6
2.08
2.01
mmol/l
0.04
33
95
100
499
3.40
14.02
2.9
2.0
72.71
76.10
nmol/l
0.55
93
436
28
61
5.29
12.64
2.0
1.8
1.70
1.41
g/l
0.72
23
52
60
233
3.42
12.43
2.0
1.8
—
—
—
0
0
35
94
4.42
12.30
2.5
1.6
—
—
—
0
0
85
410
3.12
12.18
6.0
3.6
26.49
4.73
mg/mmol
2.51
69
253
50
175
3.62
12.14
1.9
1.7
—
—
—
0
0
125
760
3.36
11.78
14.0
10.2
4.67
4.02
e9/l
2.59
115
680
49
176
3.49
11.37
1.8
1.7
—
—
—
0
0
53
204
3.31
10.98
1.3
1.2
30.04
9.69
u/ml
0.88
19
75
46
165
3.44
10.64
11.2
8.6
1.34
1.36
mmol/l
0.01
34
131
32
90
4.14
10.52
14.3
6.5
89.74
93.82
%
0.70
32
90
99
551
2.88
10.49
2.5
2.0
75.68
95.91
pmol/l
4.95
61
304
80
400
2.87
10.36
2.3
2.0
150.42
171.91
u/l
0.35
74
371
112
684
2.83
9.64
20.7
15.0
1.32
1.33
inr
0.04
28
198
39
135
3.44
9.46
12.5
9.9
115.90
124.47
g/l
1.45
39
129
28
78
4.09
9.28
1.9
1.3
—
—
—
0
0
68
330
2.75
9.10
2.9
2.0
3.85
3.30
mg/l
0.93
60
288
91
516
2.62
8.84
6.1
2.9
—
—
—
0
0
81
442
2.57
8.42
6.2
3.1
3184.13
1104.67
ng/l
1.70
73
372
90
518
2.55
8.34
5.2
2.4
224.87
157.40
ug/l
1.02
81
473
48
208
2.81
7.83
1.5
1.3
47.11
29.92
iu/ml
0.37
18
66
24
68
3.94
7.74
8.3
2.8
56.20
46.63
%
1.10
24
68
19
45
4.62
7.69
1.4
1.2
—
—
—
0
0
35
128
3.18
7.69
3.0
2.6
3.10
7.46
ug/l
1.47
30
116
103
648
2.47
7.66
7.4
4.7
0.00
0.00
estimate
-0.00
26
118
103
653
2.44
7.46
6.1
3.6
0.00
0.00
estimate
-0.00
27
130
30
102
3.35
7.40
4.8
2.5
34.17
64.58
ml/min/173m2
6.44
18
38
137
994
2.86
7.40
7.4
4.2
21.89
12.84
mm/h
6.04
132
906
19
35
5.97
7.17
1.3
1.3
—
—
—
0
0
49
224
2.66
7.15
3.1
1.7
29.14
29.42
s
0.13
49
215
103
663
2.38
7.07
6.1
3.6
0.00
0.00
estimate
-0.00
24
117
12
11
11.62
6.91
2.3
1.1
—
—
—
0
0
18
45
4.35
6.81
1.8
1.6
—
—
—
0
0
69
380
2.36
6.71
5.3
3.0
0.65
0.38
e6/l
0.68
61
283
18
35
5.62
6.54
1.7
1.2
—
—
—
0
0
64
347
2.34
6.40
2.0
1.6
18.47
20.67
nmol/l
0.58
57
291
67
374
2.30
6.23
6.6
3.9
0.00
0.00
estimate
-0.00
21
115
77
458
2.23
6.12
3.1
3.2
2.34
2.35
mmol/l
0.32
70
394
25
86
3.23
6.03
5.7
2.7
3.33
1.72
mmol/l
0.79
15
67
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
31
5.58
5.87
4.3
2.0
0.23
0.30
u/ml
0.58
11
18
121
878
2.28
5.70
5.8
4.3
—
3690.62
—
0
16
14
24
6.25
5.66
6.1
2.3
16.88
16.23
%
—
9
12
86
552
2.12
5.48
6.6
3.6
42.69
36.81
ng/l
0.34
68
409
18
55
3.54
5.19
1.4
1.3
8.10
7.41
g/l
0.55
18
50
18
55
3.54
5.19
1.3
1.3
—
—
—
0
0
51
273
2.23
5.10
2.1
1.6
1355.19
1196.32
nmol/l
0.56
43
209
16
37
4.66
5.09
5.3
2.1
23.86
24.82
mmol/l
0.24
16
37
17
52
3.52
4.89
1.4
1.3
3.55
3.21
g/l
0.68
17
47
17
53
3.45
4.76
1.4
1.3
9.88
11.06
g/l
0.73
17
47
16
48
3.57
4.73
1.4
1.3
36.25
36.70
g/l
0.10
16
43
90
614
1.98
4.61
3.4
2.7
—
—
—
0
0
12
23
5.52
4.55
1.6
1.4
—
—
—
0
0
13
28
4.93
4.47
2.1
1.8
—
—
—
0
0
45
241
2.17
4.44
4.1
2.7
0.89
0.93
e6/l
0.05
32
142
15
38
4.22
4.42
2.1
1.7
—
—
—
0
0
12
24
5.29
4.41
2.0
1.5
—
—
—
0
0
13
29
4.76
4.35
2.1
1.4
—
—
—
0
0
15
39
4.11
4.32
2.1
1.7
—
—
—
0
0
14
35
4.26
4.21
3.4
3.1
—
4.02
—
0
5
12
27
4.70
4.02
1.8
1.4
—
—
—
0
0
13
32
4.31
4.00
2.2
1.4
—
—
—
0
0
25
108
2.54
3.98
7.8
3.6
1.22
1.22
mmol/l
0.03
25
97
78
527
1.88
3.94
6.5
3.7
—
—
—
0
0
12
30
4.22
3.67
1.4
1.5
346.71
248.33
ug/g
—
7
16
40
220
2.07
3.64
4.4
2.8
3.05
1.16
e6/l
1.00
26
122
31
154
2.24
3.64
2.3
3.2
10.15
8.81
umol/l
0.17
26
135
9
18
5.21
3.42
2.4
1.4
—
—
—
0
0
9
18
5.21
3.42
2.4
1.4
—
—
—
0
0
14
49
3.02
3.27
2.3
3.2
—
—
—
0
0
8
15
5.54
3.23
1.4
1.1
—
—
—
0
0
24
113
2.31
3.18
3.6
3.4
471.62
186.44
ng/l
1.15
24
101
10
25
4.18
3.14
2.4
1.8
—
—
—
0
0
10
25
4.18
3.14
2.4
1.8
—
—
—
0
0
154
1348
2.36
3.10
34.9
14.6
25.88
24.81
mg/l
0.18
146
1074
5
6
8.53
2.76
1.4
1.3
—
—
—
0
0
7
14
5.16
2.75
2.1
1.5
—
—
—
0
0
10
29
3.60
2.74
1.8
1.2
—
—
—
0
0
41
251
1.83
2.70
1.3
1.2
0.63
1.81
u/ml
0.75
13
64
11
35
3.29
2.70
1.6
1.2
—
—
—
0
0
28
151
2.02
2.67
5.5
3.5
—
—
—
0
0
7
15
4.82
2.62
2.7
2.2
—
—
—
0
0
7
15
4.82
2.62
2.7
2.2
—
—
—
0
0
7
15
4.82
2.62
2.7
2.2
—
—
—
0
0
11
36
3.19
2.62
1.6
1.2
—
—
—
0
0
50
328
1.74
2.61
3.3
2.4
—
—
—
0
0
32
183
1.92
2.59
22.3
6.9
—
—
—
0
0
118
970
1.69
2.58
4.9
3.6
15.26
14.96
pmol/l
0.71
107
864
6
12
5.14
2.42
1.3
1.2
—
—
—
0
0
7
17
4.24
2.38
1.9
2.1
—
—
—
0
0
138
1198
1.77
2.31
5.9
4.5
2.02
1.94
mu/l
0.36
132
1065
7
18
4.01
2.27
1.9
2.0
—
—
—
0
0
7
18
4.01
2.27
1.4
1.4
—
—
—
0
0
13
54
2.52
2.26
1.5
1.4
—
—
—
0
0
5
9
5.68
2.23
1.4
1.1
—
—
—
0
0
5
9
5.68
2.23
1.4
1.1
—
—
—
0
0
5
10
5.11
2.08
1.2
1.0
—
—
—
0
0
5
10
5.11
2.08
1.2
1.0
—
—
—
0
0
5
10
5.11
2.08
1.4
1.1
—
—
—
0
0
6
15
4.10
2.05
4.5
3.5
—
—
—
0
0
103
851
1.52
1.93
4.1
3.1
64.14
48.74
u/l
1.23
97
787
16
79
2.13
1.92
2.3
1.7
—
—
—
0
0
6
17
3.62
1.85
1.5
1.2
—
—
—
0
0
7
24
3.00
1.74
1.1
1.3
—
—
—
0
0
5
13
3.93
1.72
1.4
1.5
—
—
—
0
0
5
13
3.93
1.72
1.2
1.1
350.00
343.69
pmol/l
—
5
13
41
284
1.58
1.69
2.0
1.7
499.26
423.91
pmol/l
0.68
35
233
10
40
2.59
1.69
1.4
1.7
—
—
—
0
0
86
698
1.46
1.68
2.8
2.6
—
—
—
0
0
8
31
2.66
1.68
1.3
1.4
—
—
—
0
0
8
31
2.66
1.68
1.3
1.6
—
—
—
0
0
6
19
3.23
1.67
1.0
1.0
—
—
—
0
0
41
285
1.58
1.67
3.6
1.7
1.45
1.32
mg/l
0.13
31
220
7
26
2.76
1.60
1.4
1.3
—
—
—
0
0
7
26
2.76
1.60
1.4
1.3
—
—
—
0
0
6
20
3.07
1.59
1.0
1.2
—
—
—
0
0
6
23
2.66
1.38
3.5
3.5
53.33
56.52
%
—
6
23
5
18
2.83
1.29
7.4
2.0
4.72
3.96
nmol/l
—
5
18
139
1283
1.43
1.06
10.1
5.7
44.20
39.83
mmol/mol
3.96
133
1178
5
22
2.31
1.04
2.0
1.8
—
—
—
0
0
147
1380
1.45
0.92
7.0
4.9
2.46
2.73
mmol/l
3.09
140
1249
144
1348
1.42
0.91
6.3
4.4
4.30
4.60
mmol/l
2.71
136
1232
6
29
2.11
0.90
2.0
1.3
—
—
—
0
0
143
1340
1.40
0.87
6.1
4.4
1.26
1.44
mmol/l
5.40
135
1210
6
32
1.91
0.82
2.7
1.3
—
—
—
0
0
157
1501
1.53
0.79
52.7
21.4
38.45
40.49
%
2.97
143
1401
7
40
1.78
0.72
2.1
2.1
—
—
—
0
0
138
1298
1.32
0.71
5.8
4.0
1.78
1.27
mmol/l
7.92
129
1163
22
163
1.40
0.68
4.0
4.6
3.28
69.70
ug/l
0.79
17
139
7
43
1.65
0.67
2.6
2.5
—
—
—
0
0
5
28
1.81
0.66
1.4
1.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.8
—
—
—
0
0
139
1332
1.23
0.45
6.3
4.7
6.53
6.00
mmol/l
3.24
130
1205
0
16
0.00
0.41
0.0
1.1
—
1.65
—
0
9
73
671
1.15
0.37
4.2
5.2
2.53
2.77
ug/l
0.11
65
599
20
163
1.26
0.36
1.6
1.4
—
—
—
0
0
8
66
1.22
0.27
2.1
3.7
15.13
1766.45
u/ml
—
8
55
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
131
1282
1.09
0.15
32.1
13.7
62.59
77.38
ml/min/173m2
8.01
122
1081
53
551
0.94
0.09
3.9
4.6
22.55
20.80
%
0.42
31
285
6
57
1.05
0.08
1.3
1.0
—
—
—
0
0
13
119
1.10
0.06
1.5
1.4
—
—
—
0
0
20
190
1.06
0.04
5.7
4.5
29.07
32.46
%
0.80
15
126
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
8.12
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
212.83
—
0
6
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
104.00
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERURI and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERURI | 2.552 [1.94, 3.35] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.157 |
During the follow-up period (1.1.1998 — 31.12.2019), 188 out of 407 females with E4_HYPERURI died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERURI | 2.743 [1.91, 3.95] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 494 males with E4_HYPERURI died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERURI.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.153% | 0.478% |
| 5 | 1.103% | 2.974% |
| 10 | 3.035% | 7.543% |
| 15 | 5.976% | 13.46% |
| 20 | 10.95% | 22.07% |
Relationships between endpoints
↥Index endpoint: E4_HYPERURI – Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data